Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide.
Solid track record with adequate balance sheet.
Share Price & News
How has Thermo Fisher Scientific's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TMO's share price has been volatile over the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: TMO exceeded the US Life Sciences industry which returned 10.4% over the past year.
Return vs Market: TMO exceeded the US Market which returned 5% over the past year.
Price Volatility Vs. Market
How volatile is Thermo Fisher Scientific's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StIs Thermo Fisher Scientific Inc. (NYSE:TMO) Worth US$278 Based On Its Intrinsic Value?
3 months ago | Simply Wall StWhy Thermo Fisher Scientific Inc. (NYSE:TMO) Could Be Worth Watching
5 months ago | Simply Wall StThermo Fisher Scientific Inc. (NYSE:TMO) Insiders Have Been Selling
Is Thermo Fisher Scientific undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: TMO ($382.27) is trading above our estimate of fair value ($253.48)
Significantly Below Fair Value: TMO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TMO is poor value based on its PE Ratio (41.6x) compared to the Life Sciences industry average (36.3x).
PE vs Market: TMO is poor value based on its PE Ratio (41.6x) compared to the US market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: TMO is poor value based on its PEG Ratio (2.5x)
Price to Book Ratio
PB vs Industry: TMO is good value based on its PB Ratio (5.3x) compared to the US Life Sciences industry average (5.8x).
How is Thermo Fisher Scientific forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TMO's forecast earnings growth (16.9% per year) is above the savings rate (2.2%).
Earnings vs Market: TMO's earnings (16.9% per year) are forecast to grow slower than the US market (22.8% per year).
High Growth Earnings: TMO's earnings are forecast to grow, but not significantly.
Revenue vs Market: TMO's revenue (6.4% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: TMO's revenue (6.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TMO's Return on Equity is forecast to be low in 3 years time (18.8%).
How has Thermo Fisher Scientific performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TMO has high quality earnings.
Growing Profit Margin: TMO's current net profit margins (14.3%) are higher than last year (12.9%).
Past Earnings Growth Analysis
Earnings Trend: TMO's earnings have grown by 15.3% per year over the past 5 years.
Accelerating Growth: TMO's earnings growth over the past year (15.7%) exceeds its 5-year average (15.3% per year).
Earnings vs Industry: TMO earnings growth over the past year (15.7%) exceeded the Life Sciences industry 9.7%.
Return on Equity
High ROE: TMO's Return on Equity (12.8%) is considered low.
How is Thermo Fisher Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: TMO's short term assets ($12.7B) exceed its short term liabilities ($5.5B).
Long Term Liabilities: TMO's short term assets ($12.7B) do not cover its long term liabilities ($24.6B).
Debt to Equity History and Analysis
Debt Level: TMO's debt to equity ratio (67.4%) is considered high.
Reducing Debt: TMO's debt to equity ratio has reduced from 74.5% to 67.4% over the past 5 years.
Debt Coverage: TMO's debt is well covered by operating cash flow (24.3%).
Interest Coverage: TMO's interest payments on its debt are well covered by EBIT (9.7x coverage).
What is Thermo Fisher Scientific current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: TMO's dividend (0.23%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.67%).
High Dividend: TMO's dividend (0.23%) is low compared to the top 25% of dividend payers in the US market (4.5%).
Stability and Growth of Payments
Stable Dividend: TMO is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: TMO is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: TMO is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TMO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Marc Casper (52yo)
Mr. Marc N. Casper has been the Chief Executive Officer and President of Thermo Fisher Scientific, Inc. since October 15, 2009 and also has been its Chairman of the Board of Directors since February 26, 20 ...
CEO Compensation Analysis
Compensation vs Market: Marc's total compensation ($USD19.02M) is above average for companies of similar size in the US market ($USD11.50M).
Compensation vs Earnings: Marc's compensation has been consistent with company performance over the past year.
|CEO, President & Chairman||10.75yrs||US$19.02m||0.087% $131.6m|
|Senior VP & CFO||4.92yrs||US$5.20m||0.0096% $14.5m|
|Executive VP & COO||2.92yrs||US$9.41m||0.026% $39.4m|
|Senior VP & President of Regions||9.5yrs||US$3.97m||0.0011% $1.7m|
|Executive Vice President||2.92yrs||US$6.01m||0.0046% $7.0m|
|VP & Chief Accounting Officer||19.5yrs||no data||0.0046% $7.0m|
|Senior VP & Chief Information Officer||1yr||no data||no data|
|Vice President of Investor Relations||13.67yrs||no data||no data|
|Senior VP & General Counsel||2.5yrs||no data||0.0018% $2.7m|
|Vice President of Corporate Communications||no data||no data||no data|
Experienced Management: TMO's management team is considered experienced (4.9 years average tenure).
|CEO, President & Chairman||10.75yrs||US$19.02m||0.087% $131.6m|
|Independent Director||13.67yrs||US$347.33k||0.019% $28.5m|
|Independent Director||12.17yrs||US$351.18k||0.0047% $7.2m|
|Lead Independent Director||0.42yr||US$350.62k||0.0039% $5.8m|
|Independent Director||20.17yrs||US$505.62k||0.0055% $8.3m|
|Independent Director||9.58yrs||US$360.62k||0.0032% $4.9m|
|Independent Director||4.17yrs||US$335.62k||0.0022% $3.3m|
|Director & Member of Scientific Advisory Board||no data||US$350.62k||0.0018% $2.7m|
|Member of Scientific Advisory Board||8.33yrs||no data||no data|
|Independent Director||3.33yrs||US$321.77k||0.00079% $1.2m|
Experienced Board: TMO's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Thermo Fisher Scientific Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Thermo Fisher Scientific Inc.
- Ticker: TMO
- Exchange: NYSE
- Founded: 1956
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$150.978b
- Shares outstanding: 394.95m
- Website: https://www.thermofisher.com
Number of Employees
- Thermo Fisher Scientific Inc.
- 168 Third Avenue
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TMO||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1980|
|TN8||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1980|
|TMO *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1980|
|TFS||SWX (SIX Swiss Exchange)||Yes||Common Stock||CH||CHF||Jan 1980|
|0R0H||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 1980|
|TN8||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jan 1980|
|TMOF||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jan 1980|
|TMOS34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH REPR 1/4 COM USD1||BR||BRL||Apr 2016|
|TMO||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH 11 REP 1 COM USD1.00||AR||ARS||Apr 2019|
Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and research and industrial markets, as well as clinical laboratories. The company’s Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems and antibody tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; cancer diagnosis and medical research products; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, and ultralow-temperature freezers and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics and chemicals; and pharma services. It has collaboration with WuXi Diagnostics and Mayo Clinic to develop antibodies tests; a strategic collaboration with Schrödinger, Inc. to expand structure-based drug discovery to novel targets using Cryo-EM; and an agreement with Daiichi Sankyo to co-develop a companion diagnostic. The company was incorporated in 1956 and is headquartered in Waltham, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/06 23:52|
|End of Day Share Price||2020/07/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.